863 In vitro and in vivo studies establish DuoBody®-CD3xB7H4 as a novel drug candidate for the treatment of solid cancers

• Kate Sasser,
• Esther Breij,
• Mischa Houtkamp,
• Stefanie De Poot,
• Louise Koopman,
• Laura Smits-de Vries,
• Frederikke Lihme Egerod,
• Sebastiaan Wubben,
• Madelon Paauwe,
• Edward van den Brink,
• Andrea Gorlani,
• Dennis Verzijl

Affiliations

Kate Sasser

Genmab, Princeton, NJ, USA

Esther Breij

2Genmab A/S, Utrecht, Netherlands

Mischa Houtkamp

Genmab, Utrecht, Netherlands

Stefanie De Poot

Genmab, Utrecht, Netherlands

Louise Koopman

Genmab, Utrecht, Netherlands

Laura Smits-de Vries

Genmab, Utrecht, Netherlands

Frederikke Lihme Egerod

Genmab, Utrecht, Netherlands

Sebastiaan Wubben

Genmab, Utrecht, Netherlands

Madelon Paauwe

Genmab, Utrecht, Netherlands

Edward van den Brink

Genmab, Utrecht, Netherlands

Andrea Gorlani

Genmab, Utrecht, Netherlands

Dennis Verzijl

Genmab, Utrecht, Netherlands